APEIRON Biologics AG

APEIRON shareholders approve new group structure geared towards enabling innovation and growth

APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01

APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

APEIRON Biologics Announces Changes to Management and Supervisory Boards

APEIRON Biologics’ APN01 selected for large-scale US trial in COVID-19

APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial

APEIRON Biologics: Patient recruitment completed in Phase II COVID-19 Clinical Trial of APN01

APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

APEIRON Biologics AG strengthens shareholder structure and Supervisory Board with international anchor investor

THE LANCET publishes promising data of APEIRON’s APN01 (rhsACE2) to treat COVID-19 in named patient use

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19

APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01

APEIRON Biologics Initiates Phase II Clinical Trial of APN01 for Treatment of COVID-19

APEIRON startet klinische Pilotstudie in China mit Medikamentenkandidat für Atemwegserkrankungen zur Behandlung der Coronavirus-Erkrankung COVID-19

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China

APEIRON to present preclinical data at the 2019 AACR-NCI-EORTC Conference

APEIRON Announces Collaboration with Lead Discovery Center GmbH

APEIRON Expands Executive Board and Appoints Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)

APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor

APEIRON to Present Clinical Data on Two Immunotherapy Programs at the 2018 ASCO Annual Meeting

APEIRON Biologics AG: Apeiron Signs Regional License Agreements for the Commercialization of its Neuroblastoma Therapy